Sagimet Biosciences (SGMT) Cash & Equivalents (2022 - 2026)

Sagimet Biosciences' Cash & Equivalents history runs 5 years deep, the most recent figure standing at $36.6 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 43.41% year-over-year to $36.6 million in Q1 2026; TTM through Mar 2026 was $36.6 million, a 43.41% decrease from a year earlier, with the FY2025 full-year figure at $35.0 million, down 53.82% from the prior year.
• Cash & Equivalents improved to $36.6 million in Q1 2026 per SGMT's latest filing, from $35.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $176.8 million in Q1 2024 and bottomed at $158000.0 in Q4 2022.
• The 5-year median for Cash & Equivalents is $64.7 million (2025), against an average of $64.0 million.
• Across the five-year window, Cash & Equivalents jumped 47456.33% in 2023 and sank 63.39% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $158000.0 in 2022, then soared by 47456.33% to $75.1 million in 2023, then grew by 0.93% to $75.8 million in 2024, then slumped by 53.82% to $35.0 million in 2025, then advanced by 4.58% to $36.6 million in 2026.
• Per Business Quant, the three latest SGMT Cash & Equivalents figures stand at $36.6 million (Q1 2026), $35.0 million (Q4 2025), and $32.5 million (Q3 2025).